Home > Urology > EAU 2020 > Prostate Cancer & Imaging > Docetaxel + hormonal therapy: improved prostate cancer PFS

Docetaxel + hormonal therapy: improved prostate cancer PFS

Presented By
Dr Andreas Josefsson , Sahlgrenska University Hospital, Sweden
Conference
EAU 2020
Trial
Phase 3, SPCG-14
Adding docetaxel to antiandrogen treatment improves progression-free survival (PFS) in prostate cancer patients with prostate-specific antigen (PSA) relapse. Dr Andreas Josefsson (Sahlgrenska University Hospital, Sweden) presented the SPCG-14 study, a prospective, multicentre, phase 2 clinical trial of bicalutamide alone or in combination with docetaxel in non-metastatic prostate cancer with a rising PSA [1]. This trial assessed whether any benefit is gained by adding docetaxel-based chemotherapy to hormonal therapy in the population of prostate cancer patients who have only biochemically relapsed disease after curative treatment (PSA doubling time <12 months). The investigators further hypothesised that the approach is likely to be more effective at a time of minimal tumour burden, prior to radiographic relapse, resulting in minimisation of the over...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on